KING PHARMACEUTICALS, INC. - FORM 8-K
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 7, 2004

King Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)

         
Tennessee
(State or other jurisdiction
of incorporation)		   0—24425
(Commission
File Number) 		  54-1684963
(IRS Employer
Identification Number)
     
501 Fifth Street, Bristol, Tennessee
(Address of principal executive offices)		   37620
(Zip Code)

Registrant’s telephone number, including area code: 423-989-8000

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

     Item 4.02(a). Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review.

     Filed as Exhibit 99.1 is a copy of the press release of King Pharmaceuticals, Inc. issued on December 8, 2004.

     Item 9.01. Financial Statements and Exhibits

     (c) Exhibits.

Exhibits:

     
Exhibit    
Number
   Description of Exhibit
99.1
  Press Release of King Pharmaceuticals, Inc. dated December 8, 2004.

 

 

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
Date: December 9, 2004 KING PHARMACEUTICALS, INC.  
 
  By:   /s/ James R. Lattanzi    
    James R. Lattanzi   
    Chief Financial Officer